Published: Oct 02, 2020 By Alex Keown
Watertown, Mass.-based C4 Therapeutics priced its upsized initial public offering at $19 per share for gross proceeds of $182.4 million.
Company stock began trading on the Nasdaq this morning under the ticker symbol CCCC. The upsized IPO is expected to close Oct. 6. C4 Therapeutics will use proceeds from the IPO to support the development of its multiple degrader drug candidates to human proof-of-concept, as well as expand the company’s operations. C4 is developing a new class of targeted protein degradation (TPD) therapeutics for a broad range of diseases.
The company, founded in 2015, is advancing two types of protein degraders, MonoDacs and BiDacs, each of which is intended to result in the same endpoint, which is the specific degradation of the target proteins of interest. ……………
Read More：https://www.biospace.com/article/c4-therapeutics-raises-182-million-in-upsized-ipo/
